May 21, 2021. Student nurse Dario Gomez, center, disinfects a chair after administering the Pfizer COVID-19 vaccine to a patient at Providence Edwards Lifesciences vaccination site in Santa Ana, Calif. U.S.AP Photo/Jae C. Hong

The coronavirus is a rapidly developing news story, so some of the content in this article might be out of date. Check out our most recent coverage of the coronavirus crisis, and subscribe to the Mother Jones Daily newsletter.

More good vaccine news is here: According to new data, the Pfizer coronavirus vaccine has “high levels of effectiveness” against the highly transmissible variant found in India. The data, from Public Health England, an agency in the UK department of health, studied Pfizer’s efficacy after two doses and found it was 88 percent effective in preventing symptomatic cases of the B.1.617.2 variant. 

Researchers found that the Pfizer shot is also highly effective against B.117, the variant first found in the UK, preventing 93 percent of symptomatic cases. And as with other variants, “even higher levels of effectiveness are expected against hospitalisation and death” after the second dose, according to the UK officials. Researchers also studied the effectiveness of the AstraZeneca vaccine, which has been used widely in the UK but has not yet been approved in the US; data shows it was was 60 percent effective against the B.1.617.2 variant, and 66 percent effective against B.117.

While the number of coronavirus cases and deaths have dropped in the United States as more people get vaccinated, the pandemic is not over yet. Other countries across the world are seeing the opposite trajectory, with more deaths and more confirmed cases. As Saturday’s announcement confirmed the efficacy of the vaccines against new variants, we passed the 165 million mark of coronavirus cases worldwide. Data from Johns Hopkins University shows that globally almost 3.5 million people have died from the virus. 

LESS DREADING, MORE DOING

This is the rubber-meets-road moment: the early days in our first fundraising drive since we took a big swing and merged with CIR to bring fearless investigative reporting to the internet, radio, video, and everywhere else that people need an antidote to lies and propaganda.

Donations have started slow, and we hope that explaining, level-headedly, why your support really is everything for our reporting will make a difference. Learn more in “Less Dreading, More Doing,” or in this 2:28 video about our merger (that literally just won an award), and please pitch in if you can right now.

payment methods

LESS DREADING, MORE DOING

This is the rubber-meets-road moment: the early days in our first fundraising drive since we took a big swing and merged with CIR to bring fearless investigative reporting to the internet, radio, video, and everywhere else that people need an antidote to lies and propaganda.

Donations have started slow, and we hope that explaining, level-headedly, why your support really is everything for our reporting will make a difference. Learn more in “Less Dreading, More Doing,” or in this 2:28 video about our merger (that literally just won an award), and please pitch in if you can right now.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate